Abstract: Diabetic retinopathy is a serious complication of diabetes mellitus, especially proliferative diabetic retinopathy(PDR), which is a leading cause of visual impairment and blindness among workingage people. In recent years, the efficacy of vascular endothelial growth factor inhibitor (Bevacizumab) has been recognized for the treatment of PDR. Intravitreal bevacizumab can accelerate absorption of vitreous hemorrhage and inhibit neovascularization, alleviate macular edema and vascular leakage and decrease the incidence of retinal detachment.  (Int Rev Ophthalmol, 2014, 38:   400-402)